Evidence map›Paper›PMID 29320952›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2019

Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients.

Riley Bove, Brain C Healy, Alexander Musallam, Pejvak Soltany, Camilo Diaz-Cruz, Neda Sattarnezhad, Bonnie I Glanz, Pia Kivisäkk, Karen K Miller, Tanuja Chitnis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Is Obesity a Modifiable Risk Factor in Multiple Sclerosis? Mechanistic Insights into Neuroinflammation and Oxidative Damage.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Immune cell metabolism in autoimmunity.Clinical and experimental immunology · 2019
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Riley BovePartners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA/Harvard Medical School, Boston, MA, USA/ Ann Romney Center for Neurologic Disease, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Brain C HealyPartners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA/Harvard Medical School, Boston, MA, USA/Ann Romney Center for Neurologic Disease, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA/Massachusetts General Hospital's Biostatistics Center, Boston, MA, USA.
Alexander MusallamPartners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
Pejvak SoltanyAnn Romney Center for Neurologic Disease, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Camilo Diaz-CruzPartners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
Neda SattarnezhadPartners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
Bonnie I GlanzPartners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA/Harvard Medical School, Boston, MA, USA/ Ann Romney Center for Neurologic Disease, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Pia KivisäkkHarvard Medical School, Boston, MA, USA/Ann Romney Center for Neurologic Disease, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Karen K MillerHarvard Medical School, Boston, MA, USA/Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA, USA.
Tanuja ChitnisPartners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA/Harvard Medical School, Boston, MA, USA/ Ann Romney Center for Neurologic Disease, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Brigham and Women's Hospital · USHarvard University · US

Funding

Harvard Clinical and Translational Science Center (UL1)UL1TR000170 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2012 to 2013
$31.4M
Hormones/Genes in Women's Health: From Bench to BedsideK12HD051959 · NICHD · BRIGHAM AND WOMEN'S HOSPITAL · PI GOLDSTEIN, JILL M, REXRODE, KATHRYN M · 2005 to 2023
$8.8M
Growth Hormone and Cardiovascular DiseaseK24HL092902 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, KAREN K · 2010 to 2019
$1.6M
NCATS NIH HHS UL1 TR000170NHLBI NIH HHS K24 HL092902NIA NIH HHS L30 AG048592NICHD NIH HHS K12 HD051959
6 · The paper itself

Abstract

backgroundIncreased adiposity is a risk factor for multiple sclerosis (MS) and is associated with increased disability scores. Adipokines may mediate the effects of adiposity on MS disease course.

objectiveThe objective of this study is to examine the association between the adipokines (leptin and fatty acid binding protein-4, FABP4) and clinical course in individuals with MS.

methodsSubjects (18-65 years) with relapsing-remitting MS or clinically isolated syndrome and <10 year disease duration were selected from a longitudinal clinical study. Cross-sectional and longitudinal models assessed the relationship between two adipokines (leptin and FABP4) and disease severity in women and men, adjusting for age, disease duration and disease type, Vitamin D level, testosterone level, and as well by body mass index (BMI).

resultsMean age of subjects ( N = 163, 56% women) was 39.3 years. Higher FABP4 levels were associated with higher Expanded Disability Status Scale (EDSS) scores in women in both univariate and multivariate analyses (odds ratio: 1.30; p = 0.005). In men, higher FABP4 level was significantly associated with change in EDSS over time (estimate: 0.0062; p = 0.035). We found no association of FABP4 levels with time to next relapse or a measure of processing speed.

conclusionFABP4 levels may be associated with increased disability in both men and women with MS independent of effects of BMI and other hormones. Future studies should expand these analyses and further explore downstream mechanisms of adiposity-related effects in MS.

Indexed as

AdiposityBody Mass IndexAdultFatty Acid-Binding ProteinsFemaleHumansLeptinLongitudinal StudiesMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingPersons with DisabilitiesSeverity of Illness IndexSex FactorsFABP4 protein, humanFatty Acid-Binding ProteinsLEP protein, humanLeptinBody mass indexfatty acid binding proteingenderleptinmultiple sclerosis

Identifiers

PMID29320952
PMCPMC6026579
OpenAlexW2783096003

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.